Groupama Asset Managment Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Groupama Asset Managment decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 20.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 229,057 shares of the biopharmaceutical company's stock after selling 60,044 shares during the period. Groupama Asset Managment's holdings in Pfizer were worth $6,052,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter valued at $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company's stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research firms recently commented on PFE. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Finally, Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Trading Up 0.8 %

Shares of NYSE PFE traded up $0.19 on Wednesday, reaching $24.73. 41,783,008 shares of the company traded hands, compared to its average volume of 39,243,727. Pfizer Inc. has a fifty-two week low of $24.33 and a fifty-two week high of $31.54. The company has a 50 day moving average of $25.98 and a 200 day moving average of $26.83. The stock has a market capitalization of $140.26 billion, a PE ratio of 17.54, a P/E/G ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the previous year, the company earned $0.10 EPS. The business's quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.